Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17293555 | 1.00 | PREP (0.49) | PREPALDH1A1OPRK1 | |
| SCHEMBL1816285 | 0.91 | PREP (0.51) | PREPALDH1A1OPRK1 | |
| SCHEMBL28943687 | 0.91 | PREP (0.51) | PREPALDH1A1OPRK1 | |
| SCHEMBL1189714 | 0.88 | PREP (0.50) | PREPALDH1A1OPRK1 | |
| SCHEMBL24555463 | 0.87 | PREP (0.48) | PREPALDH1A1OPRK1 | |
| SCHEMBL2084198 | 0.85 | PREP (0.48) | PREP | |
| SCHEMBL205549 | 0.84 | — | — | |
| SCHEMBL30578076 | 0.84 | — | — | |
| SCHEMBL10039818 | 0.84 | — | — | |
| SCHEMBL22811016 | 0.84 | PREP (0.45) | PREPALDH1A1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301994-A9 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2023-09-28 | — | — | US | disclosed |
| US-20230301994-A9 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2023-09-28 | — | — | US | disclosed |
| US-20220387426-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LTD (NZ) | 2022-12-08 | — | — | US | disclosed |
| CN-115243688-A | Bicyclic compounds and methods of their use in treating PITT HOPKINS syndrome | 诺仁制药有限公司 | 2022-10-25 | — | — | CN | disclosed |
| US-11197856-B2 | Bicyclic compounds and methods for their use in treating autism | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2021-12-14 | — | — | US | disclosed |
| WO-2021080646-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2021-04-29 | — | — | WO | disclosed |
| US-20200163961-A1 | Bicyclic Compounds and Methods for Their Use in Treating Autistic Disorder and Autism | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2020-05-28 | — | — | US | disclosed |
| CN-107027306-B | 1- (cyclopent-2-en-1-yl) -3- (2-hydroxy-3- (arylsulfonyl) phenyl) urea derivatives as CXCR2 inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10548892-B2 | Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2020-02-04 | — | — | US | disclosed |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-02 | — | — | US | disclosed |
| US-20070298009-A1 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-12-27 | — | — | US | disclosed |
| US-20070298009-A1 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-12-27 | — | — | US | disclosed |
| US-20070298009-A1 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-12-27 | — | — | US | disclosed |
| US-20070197511-A1 | Neuroprotective bicyclic compouds and methods for their use | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-08-23 | — | — | US | disclosed |
| US-20070004641-A1 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-01-04 | — | — | US | disclosed |
| US-20070004641-A1 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-01-04 | — | — | US | disclosed |
| US-20070004641-A1 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-01-04 | — | — | US | disclosed |
| US-20060258663-A1 | Cyclic G-2AllylProline in treatment of Parkinson's disease | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-16 | — | — | US | disclosed |
| US-20060251649-A1 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-09 | — | — | US | disclosed |
| US-20060251649-A1 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070298009-A1 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration | GRM2, GRM1, GLUL | PREP 48/4885ALDH1A1 4078/4885OPRK1 2055/4885 |
| US-10548892-B2 | Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders | GRIN2C, GRIN2D, GRIA2 | PREP 203/4885ALDH1A1 1322/4885OPRK1 1397/4885 |
| US-20230301994-A9 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | QPCT, GRIA2, GGPS1 | PREP 257/4885ALDH1A1 1440/4885OPRK1 1079/4885 |
| US-11197856-B2 | Bicyclic compounds and methods for their use in treating autism | GRIN2C, ADCYAP1R1, GRIA2 | PREP 91/4885ALDH1A1 1398/4885OPRK1 1483/4885 |
| US-20220387426-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | QPCT, GRIA2, GGPS1 | PREP 257/4885ALDH1A1 1440/4885OPRK1 1079/4885 |
| US-20200163961-A1 | Bicyclic Compounds and Methods for Their Use in Treating Autistic Disorder and Autism | ADCYAP1R1, GRIN2C, ADCY2 | PREP 76/4885ALDH1A1 1206/4885OPRK1 1354/4885 |
| US-20060251649-A1 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | GRM2, GRIN2C, GRIN2A | PREP 90/4885ALDH1A1 2555/4885OPRK1 2179/4885 |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | CXCR2, CXCR1, CXCR3 | PREP 946/4885ALDH1A1 1449/4885OPRK1 353/4885 |
| US-20070197511-A1 | Neuroprotective bicyclic compouds and methods for their use | NLN, GAP43, BAD | PREP 616/4885ALDH1A1 1316/4885OPRK1 103/4885 |
| US-20060258663-A1 | Cyclic G-2AllylProline in treatment of Parkinson's disease | PARK7, ADCYAP1R1, LRRK2 | PREP 40/4885ALDH1A1 2502/4885OPRK1 502/4885 |
| US-20070004641-A1 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate | CHAT, GAP43, BCHE | PREP 109/4885ALDH1A1 2612/4885OPRK1 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.